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Abstract
Tumor progression alters the composition and physical properties
of the extracellular matrix. Particularly, increased matrix stiffness
has profound effects on tumor growth and metastasis. While
endothelial cells are key players in cancer progression, the influ-
ence of tumor stiffness on the endothelium and the impact on
metastasis is unknown. Through quantitative mass spectrometry,
we find that the matricellular protein CCN1/CYR61 is highly
regulated by stiffness in endothelial cells. We show that stiffness-
induced CCN1 activates b-catenin nuclear translocation and signal-
ing and that this contributes to upregulate N-cadherin levels
on the surface of the endothelium, in vitro. This facilitates
N-cadherin-dependent cancer cell–endothelium interaction. Using
intravital imaging, we show that knockout of Ccn1 in endothelial
cells inhibits melanoma cancer cell binding to the blood vessels, a
critical step in cancer cell transit through the vasculature to
metastasize. Targeting stiffness-induced changes in the vascula-
ture, such as CCN1, is therefore a potential yet unappreciated
mechanism to impair metastasis.
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Introduction
Tumor cells and cancer-associated fibroblasts (CAFs) influence the
extracellular matrix via increased matrix deposition and modifi-
cation (Kalluri & Zeisberg, 2006; Pickup et al, 2014). The tumor
matrix typically consists of excessive levels of fibrous collagen,
which can be additionally crosslinked by soluble mediators such as
lysyl oxidase (LOX), thereby elevating matrix stiffness (Butcher
et al, 2009). In turn, the increased matrix stiffness can have a
profound effect on cancer progression inducing oncogenic intracel-
lular signaling to aid tumorigenesis, including activation of FAK,
AKT, b-catenin, and PI3K, and inhibition of the tumor suppressor
genes PTEN and GSK3a/b (Mouw et al, 2014). Increased tumor
stiffness not only impacts cancer cells but its effects similarly extend
to the surrounding stromal cells, where matrix stiffness can activate
fibroblasts to a CAF phenotype and maintain it via the mechanosen-
sitive transcription factor YAP (Georges et al, 2007; Calvo et al,
2013). In addition, matrix stiffness correlates with the number of
tumor-activated macrophages (Acerbi et al, 2015). Therefore, tumor
matrix stiffness is becoming an appealing target for therapeutic
intervention (Jarvelainen et al, 2009; Cox & Erler, 2011). Targeting
tumor stiffness via the inhibition of LOX activity has been shown
to decrease tumor growth, malignancy, and metastasis in mice
(Levental et al, 2009; Miller et al, 2015). Furthermore, solid stress
within tumors was reduced with an angiotensin inhibitor, resulting
in CAF inactivation and reduced collagen and hyaluronan levels,
even in established tumor matrices (Chauhan et al, 2013). These
studies support tumor microenvironment stiffness as a therapeutic
target to perturb cancer development and progression.
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A crucial element to cancer metastasis is the vascular endothe-
lium. While normally acting as a physiological barrier, during
tumorigenesis the vasculature provides a major route for cancer
cell dissemination to distant sites. Despite the known
consequences that tumor matrix stiffness has on cancer cells and
fibroblasts to aid cancer metastasis, whether the matrix stiffness
sets up a similar feedback with the endothelium to facilitate cancer
cell entry and exit from the vasculature is a fundamental, yet
unaddressed issue.
We sought to determine how primary human umbilical vein
endothelial cells (HUVECs referred to as ECs) responded to matrices
of low (400 Pa) or high (22,000 Pa) stiffness, using fibronectin-
coated polyacrylamide gels (PAGs) that mimic normal or trans-
formed tissue, respectively (Butcher et al, 2009; Levental et al,
2009).
Results
High stiffness induces phenotypic and cell signaling alterations
in endothelial cells
ECs cultured at increasing levels of matrix stiffness displayed corre-
sponding increases in proliferation, as assessed by EdU incorpora-
tion (Fig 1A), spread area (Fig 1B), and activation of MLC, FAK,
AKT, and ERK1/2 (Fig 1C and D). These results recapitulated
responses to stiffness in other studies (Ghosh et al, 2008; Wood
et al, 2011) and validated our model of the endothelium response to
differing matrix stiffness.
To assess how the proteome of ECs is affected by tumor stiffness,
we combined the most accurate quantitative approach, Stable
Isotope Labeling of Amino acids in cell Culture (SILAC) (Ong et al,
2002), with high-resolution mass spectrometry (MS). SILAC-labeled
ECs were cultured on PAGs of differing matrix stiffness (physiologi-
cal, 400 Pa, and pathological, 22,000 Pa) for 24 h before MS analy-
sis (Fig 1E). MS analysis quantified 5,938 proteins, with 5,461 of
these with a calculated ratio between low stiffness and high stiffness
in replicate experiments, where the heavy and light labeling condi-
tions were swapped (i.e., forward and reverse experiments; Dataset
EV1). We further pinpointed 244 proteins most highly regulated in
both the forward and reverse experiments (Fig EV1A and Dataset
EV1). Next, we used STRING to map the functional and physical
protein–protein interactions (Fig EV1B) and to perform an unbiased
pathway enrichment analysis of the regulated proteins. This analy-
sis observed upregulation of proteins related to cell adhesion, meta-
bolism, and proliferation (Fig EV1C), in response to increased
stiffness, which mirrored the observed phenotype. Of note, cell
adhesion proteins included receptors involved in heterotypic cell–
cell interactions (Fig EV1D), indicating that matrix stiffness may
regulate the crosstalk between different cell types within the tumor
microenvironment.
As proliferation is a major response to increased stiffness (Fig 1A
and D), we segregated changes induced by matrix stiffness from
those induced by proliferation by comparing the proteomes of ECs
in different proliferative states seeded onto substrates of the same
stiffness (Fig 1F). This allowed us to subtract proliferation-
associated proteins to focus on the stiffness-related proteome of
ECs (Fig 1G and Dataset EV2). One of the most stiffness-regulated
proteins was the secreted protein CCN1, which is known as a pro-
angiogenic factor that binds to integrins, thus regulating intracellu-
lar signaling from the extracellular matrix (Leu et al, 2002). CCN1
possessed characteristics of a matricellular protein, being found in
cell lysates, secreted medium, and extracellular matrix extracts from
ECs, and its levels increased in all fractions when cells were stimu-
lated with high matrix stiffness (Appendix Fig S1A). Finally, inhibi-
tion of myosin with blebbistatin treatment reduced CCN1 protein
and mRNA levels at low stiffness and high stiffness, and blocked the
increase in CCN1 expression in response to high matrix stiffness
(Fig 1H and I). Similarly, we measured reduced levels of stiffness-
induced CCN1 in microvascular dermal endothelial cells (HMVECs)
upon blebbistatin treatment (Appendix Fig S1B). This indicates that
CCN1 levels are regulated by cytoskeletal tension and that elevated
levels of CCN1 are, at least in part, a bona fide response to matrix
stiffness in ECs.
Next, we assessed that a link between CCN1 and tumor stiffness
exists in vivo using the orthotopically transplanted mouse E0771
breast cancer cell model. In situ hybridization analysis revealed that
Ccn1 was expressed in cancer and stromal cells, including blood
vessels (Fig 2A). High Ccn1 expression was found only in some
regions of the tumor which were adjacent to the necrotic areas
(Appendix Fig S1C). Quantification of collagen I and III fibers in
tumor regions with high (peri-necrotic areas) or low Ccn1 expres-
sion by Sirius red staining showed that higher collagen content asso-
ciated with high Ccn1 expressing regions (Fig 2A and B). Finally,
atomic force microscopy analysis of the tissues determined that
peri-necrotic tumor areas (bona fide highly expressing Ccn1) were
much stiffer than the non-necrotic areas and that stiffness was
within a range comparable to those recapitulated in vitro with the
PAGs (Fig 2C). Hence, an association between CCN1 and stiffness
can be found in vivo and we investigated further the role of CCN1 in
endothelial cells in the tumor context.
CCN1 regulates N-cadherin expression
First, we deciphered the mechanism by which CCN1 may affect
endothelial cells and that could be relevant in a tumor context.
Notably, efficient silencing of CCN1 in ECs using a pool of siRNA
minimally altered the stiffness-induced proliferation and spreading
of ECs after 24 h of culture (Fig EV2A–C). This suggests that at least
in our system, CCN1 does not function as a general regulator of
proliferation or cell–matrix adhesion. We reasoned that CCN1 may
be part of the signaling response of cells to increased stiffness.
Therefore, using MS and a SILAC spike-in approach (Geiger et al,
2011), we investigated whether any of the stiffness-regulated
proteins were also regulated downstream of CCN1 (Fig 3A and
Dataset EV3). Strikingly, the levels of few proteins followed CCN1
regulation. Among these, N-cadherin/CDH2, which is notable as a
cancer cell protein that promotes metastasis (Tanaka et al, 2010),
was highly downregulated in response to CCN1 silencing (Fig 3A).
Corroborating the above results, both CCN1 and N-cadherin levels
were induced by stiffness in HMVECs (Fig EV2D and E), and CCN1
silencing with either a pool of or a single siRNA markedly reduced
the upregulation of N-cadherin induced by high matrix stiffness in
ECs and HMVECs (Figs 3B and EV2D–G). The stiffness-induced
CCN1-dependent induction of N-cadherin was specific, as the levels
of the major endothelial cadherin, VE-cadherin/CDH5, were
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unaffected by stiffness or CCN1 loss (Fig 3B). Stiffness and CCN1
have been shown to induce epithelial to mesenchymal transition
(EMT; Hou et al, 2014; Wei et al, 2015). However, here, ECs are not
undergoing EMT since the levels of the endothelial cell markers, VE-
cadherin, PECAM-1, and von Willebrand factor, were not altered, as
measured in the MS analyses. Furthermore, only N-cadherin was
increased, but not other typical mesenchymal markers, such as
Vimentin (Dataset EV3). The induction of N-cadherin expression
occurred as a transcriptional response to CCN1, as CCN1 silencing
in ECs significantly reduced N-cadherin mRNA levels to a degree
that mirrored protein levels (Fig 3C). A corresponding increase in
N-cadherin protein and mRNA levels occurred upon CCN1-GFP
overexpression (Fig 3D and E), where ectopic GFP-tagged CCN1
was abundantly expressed, secreted into the media, and similarly
localized to endogenous CCN1 in the matrix (Fig EV2H and I). The
EC response to increased stiffness thus involves CCN1-dependent
upregulation of N-cadherin expression.
CCN1-induced expression of N-cadherin requires b-catenin
We sought to determine how CCN1 controls N-cadherin upregula-
tion. We examined b-catenin (CTNNB1) as it has been shown to
be stiffness sensitive (Samuel et al, 2011), involved in CCN1-
dependent signaling (Xie et al, 2004) and regulates N-cadherin
expression (Lamouille et al, 2014). First, we ascertained that stiff-
ness-induced CCN1 controlled b-catenin levels. The levels of
b-catenin increased with increasing matrix stiffness in ECs while
silencing CCN1 strongly reduced the levels of b-catenin, as well
as N-cadherin (Figs 4A and B, and EV2F). Next, we confirmed
that b-catenin transcriptional activity increases with matrix stiff-
ness (Fig 4C), and showed that stiffness-induced N-cadherin
required b-catenin. In ECs silenced for b-catenin, we measured
similar levels of N-cadherin when cultured at low stiffness and
high stiffness (Appendix Fig S2A). To focus specifically on CCN1-
dependent signaling, we manipulated CCN1 levels in ECs grown
at a constant stiffness (on plastic). CCN1 knockdown reduced the
transcriptional activity of b-catenin (Fig 4D). Conversely, overex-
pression of CCN1-GFP induced increased b-catenin nuclear
localization (Fig 4E and Appendix Fig S2B and C) and further
elevation in b-catenin transcriptional activity (Fig 4F). This was
associated with an increase in both N-cadherin and b-catenin
levels, and in particular active b-catenin (non-phosphorylated on
S37/T41; Maher et al, 2010; Fig 4G). This indicates that CCN1 is
a major intermediate in stiffness-induced b-catenin nuclear
translocation and transcriptional activity. Next, we explored the
requirement of b-catenin for the CCN1-dependent regulation of
N-cadherin expression. In CCN1-GFP-overexpressing cells, knock-
down of b-catenin to control levels diminished the ability of the
cells to induce upregulation of CCN1-induced N-cadherin, both
protein and mRNA, to the levels of the control cells (Fig 4G and
H, and Appendix Fig S2D). Endothelial CCN1 therefore modulates
N-cadherin expression in a b-catenin-dependent manner.
Cancer cell adhesion to the endothelium increases with matrix
stiffness and requires CCN1-induced N-cadherin
N-cadherin has a major role in mediating cellular contact during the
initial attachment of cancer cells to the endothelium. This hetero-
typic interaction is the first step of the metastatic cascade which
leads to the subsequent transendothelial migration of the cancer
cells (Qi et al, 2005; Strell et al, 2007). For this reason, we
addressed whether CCN1-dependent N-cadherin upregulation in
ECs could facilitate cancer cell interactions with ECs. First, we eval-
uated N-cadherin localization in ECs cultured at differing
stiffnesses. N-cadherin localization to peripheral cell–cell contacts
was consistently increased with matrix stiffness (Fig 5A and
Appendix Fig S3A and B). Moreover, the increase in N-cadherin
surface localization induced by elevated stiffness was strongly
reduced upon CCN1 knockdown (Fig 5A and Appendix Fig S3A and
B). In contrast, the localization of VE-cadherin at the cell periphery
was not affected by stiffness or by CCN1 knockdown (Fig 5A and
Appendix Fig S3A and B). Concordantly, silencing of CCN1 in a
monolayer of ECs did not alter its permeability (Appendix Fig S3C).
To simulate the initial process of cancer cell intravasation, we
measured the adhesion of cancer cells to a confluent monolayer of
ECs, where the lowest stiffness was replaced with 1,050 Pa. At this
◀ Figure 1. CCN1 levels are highly induced by matrix stiffness in endothelial cells.A, B HUVECs cultured for 24 h on FN-coated PAGs of differing matrix stiffness have increased proliferation, measured as percentage of cells which incorporated EdU
(3 h of incubation, Click-IT EdU Imaging kit, Invitrogen) (A), and have increased spread area (B). Bars represent mean  SEM. N = 3 average values from 3 replicate
experiments. Scale bar = 50 lm. Significance based on two-tailed unpaired t-test.
C, D Representative Western blot analysis showing that the intracellular signaling is altered in HUVECs with increasing matrix stiffness, as shown by active
phosphorylated myosin light chain (pMLC, Thr18, Ser19), active phospho-FAK (pFAK, Tyr397), active phospho-AKT (pAKT, Ser473) as well as activated phospho-ERK1
and phospho-ERK2 (pERK1, Thr202, Tyr204; pERK2, Thr185, Tyr187). GAPDH was used as a loading control.
E Schematic of the SILAC labeling approach where the heavy and light conditions are mixed to generate forward and reverse replicate experiments before being
processed for MS analysis.
F In the proliferation datasets, a heavy labeled SILAC standard was spiked into each sample and used as a reference. FASP = filter-aided sample preparation.
SAX = strong anion exchange.
G Hierarchical clustering based on average Euclidean distance and heat map based on the Z-score of the log2 averaged ratios of proteins regulated in HUVECs by
stiffness and that were quantified in the proliferation datasets (Dataset EV2). The red and blue clusters contain proteins whose levels were found more up- or
downregulated, respectively, by stiffness compared with the proliferation datasets. 22/0.4 KPa = average SILAC ratio between forward and reverse experiments of
the stiffness datasets; Prolif soft = average SILAC ratio of three replicate experiments of HUVECs cultured on Matrigel: 4 h/22 h; Prolif stiff = average SILAC ratio of
three replicates of HUVECs cultured on plastic: 1 day/4 days.
H HUVECs pre-treated with blebbistatin were seeded on FN-coated PAGs of different stiffness for 24 h in the presence of blebbistatin. Representative Western blot
showing CCN1 levels and GAPDH was used as a loading control. Quant = CCN1 intensity normalized by GAPDH intensity (analysis by Image Studio Lite software).
I HUVECs pre-treated with blebbistatin were seeded on FN-coated PAGs of different stiffness for 24 h in the presence of blebbistatin. Representative RT–PCR
analysis showing Ccn1 expression normalized by three housekeeping genes. Bars represent mean  SEM. n = 3 technical replicates.
Source data are available online for this figure.
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stiffness, cells are able to form greater substrate adhesions
(Saunders & Hammer, 2010) and they formed an intact monolayer,
while at 400 Pa we could not observe the formation of an intact
monolayer. We used the PC3 human prostate cancer line, which has
high N-cadherin levels and has been utilized previously in co-culture
with ECs (Nalla et al, 2011). PC3 cell adhesion to ECs increased with
matrix stiffness, which could be significantly abrogated by CCN1
knockdown (Fig 5B and Appendix Fig S3D). Even at the highest
levels of stiffness (culture on glass), CCN1 knockdown with a pool
of siRNA or two independent siRNAs in ECs significantly reduced
the adhesion of PC3 cells (Fig 5C and Appendix Fig S3E). The
general validity of these results was confirmed using B16F1 mouse
melanoma, Lewis lung carcinoma (LLC), and E0771 breast cancer
cell lines, which express N-cadherin when kept in culture (Fig 5D
and Appendix Fig S3F). Moreover, PC3 cells adhered less to
HMVECs and ECs expressing lower levels of N-cadherin, where
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Figure 2. Ccn1 is highly expressed in stiff regions of orthotopic E0771 tumors.
A Representative image of in situ hybridization for Ccn1 mRNA and collagen I and III fibers (Sirius red) of E0771 orthotopic tumors performed on consecutive sections
showing that there are tumor regions with high and low expression of Ccn1. The right panels show a blood vessel positive for Ccn1 staining. Scale bar = 100 lm.
B Quantification of collagen I and III fiber content based on Sirius red staining (% of the measured area) showing that higher amounts of collagen fibers are found in
regions of the tumor expressing high Ccn1 levels.
C Quantification of tumor stiffness performed by atomic force microscopy showing that higher stiffness is measured in peri-necrotic regions (bona fide expressing high
Ccn1 levels) of the tumor.
Data information: Significance according to two-tailed Mann–Whitney test. Horizontal lines and error bars represent mean  SEM. n = regions assessed from two
tumors.
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reduced levels of N-cadherin were induced upon silencing of CCN1
(Fig 5D and Appendix Fig S3G) or b-catenin (Fig 5E and
Appendix Fig S3H), respectively. Conversely, exogenous expression
of CCN1-GFP in ECs strongly enhanced PC3 cell adhesion (Fig 5F
and Appendix Fig S3I) and addition of an N-cadherin-blocking
antibody completely abrogated the ability of CCN1 to promote EC–
cancer cell interactions (Fig 5F). Moreover, stable knockdown of
N-cadherin in PC3 cells strongly decreased their adhesion to control
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D Representative Western blot analysis shows that N-cadherin protein levels increase with CCN1 overexpression in HUVECs.
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Figure 4. CCN1-induced N-cadherin regulation requires b-catenin.
A, B Representative Western blot analysis (A) and quantification (B) showing that upon silencing of CCN1 in HUVECs (single siRNA, same Western blot shown in
Fig EV2F) cultured on FN-coated PAGs of different stiffness, the levels of b-catenin (CTNNB1) are induced by stiffness to a lower extent. b-catenin levels were
normalized by GAPDH, which was used as a loading control. Quantification based on Image Studio Lite software.
C, D HUVECs cultured on plastic and transfected with a b-catenin luciferase reporter indicate that b-catenin activity increases with matrix stiffness (C) and decreases
upon CCN1 knockdown (D).
E, F Overexpression of CCN1-GFP increases b-catenin nuclear localization (E) and transcriptional activity (F).
G Representative Western blot analysis showing that the levels of N-cadherin increase with the overexpression of CCN1-GFP in ECs and that this was largely reduced
upon knockdown of b-catenin. Quant = CDH2 intensity over GAPDH intensity, which was used as a loading control. Quantification based on Image Studio Lite
analysis.
H RT–PCR analysis showing that the levels of N-cadherin increase with the overexpression of CCN1-GFP in HUVECs and that this was largely reduced upon
knockdown of b-catenin. The levels of N-cadherin were normalized to the levels of three housekeeping genes.
Data information: Bars represent mean  SEM (n = 3 replicate experiments). Significance according to the unpaired Student’s t-test.
Source data are available online for this figure.
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ECs (Fig 5G and Appendix Fig S3J). This indicates that sufficient
levels of N-cadherin in both ECs and cancer cells must be present
for EC–cancer cell interactions. Given this requirement for homo-
philic N-cadherin interactions in heterotypic cell interactions, we
tested the generality of whether CCN1 also controlled N-cadherin
expression in tumor cells and fibroblasts. Culture of immortalized
mammary normal (iNF) or pro-invasive cancer-associated fibroblasts
(iCAF; Kojima et al, 2010; Hernandez-Fernaud et al, 2017) at
increasing stiffness resulted in a corresponding increase in CCN1
levels (Appendix Fig S3K). When we cultured these cells at high
stiffness, CCN1 depletion resulted in downregulation of N-cadherin
in iNFs, iCAFs, and PC3 cells (Appendix Fig S3L). Accordingly,
stable (Fig 5G and Appendix Fig S3M) and transient (Appendix Fig
S3N) CCN1 depletion in PC3 cells resulted in strong perturbation of
adhesion to ECs (Fig 5G and Appendix Fig S3O), to levels similar to
N-cadherin depletion (Fig 5G and Appendix Fig S3J). These data
show that increased stiffness in the tumor microenvironment may
cause increased CCN1 expression and cell–cell interactions between
cancer cells, endothelial cells, and fibroblasts and that this depends
on N-cadherin.
Ccn1 knockout in the endothelium decreases cancer cell binding
to the blood vessels
We examined the requirement of CCN1 in the endothelium for
the highly metastatic B16F10 melanoma model (Fidler, 1975) to
adhere to blood vessels in vivo. Since endothelial deletion of Ccn1
postnatally can alter vessel growth in the developing mouse retina
(Chintala et al, 2015), we crossed Ccn1fl/fl mice (Fig EV3A) with
endothelial-specific Cdh5CreERT2 driver mice (Wang et al, 2010) to
delete Ccn1 in adult mice (referred to as Ccn1 KOEC). We ascertained
that Ccn1 was efficiently knocked out in the endothelium of the
Ccn1 KOEC mice and that this did not affect the vasculature. Lungs
of Ccn1 wild-type mice (Ccn1 WTEC) positively stained for Ccn1
mRNA and the staining was restricted to some regions of the lungs
(Fig EV3B and C). Ccn1 has been found expressed mostly in angio-
genic endothelial cells (Chintala et al, 2015), suggesting that Ccn1 is
expressed only in the regions of the lung that are undergoing active
vascular remodeling. Conversely, no staining was detected in the
lungs of Ccn1 KOEC mice (Fig EV3B and C). We could not detect
significant differences in the lung vasculature between Ccn1 KOEC
and Ccn1 WT mice, as measured by total amount of Pecam1+ stain-
ing (Fig EV3D and E). Similarly, endothelial knock out of Ccn1
reduced the levels of Ccn1 expression in the ear (Fig EV3F). More-
over, Ccn1 deletion reduced the expression of N-cadherin in the
lung vasculature (Fig EV3G), indicating that, also in vivo, CCN1
may control N-cadherin expression. To assess cancer cell binding to
the vasculature, fluorescently labeled B16F10 melanoma cells were
intradermally transplanted into the ear of Ccn1 KOEC and Ccn1 WTEC
mice. We accurately monitored the capability of the cancer cells to
adhere to the blood vessels by fluorescently labeling the vasculature
with an anti-Pecam1 antibody. Intravital imaging analysis revealed
that cancer cells can stably or transiently bind to blood vessels and,
strikingly, the number of cancer cells that stably adhered to the
blood vessels was significantly reduced upon depletion of Ccn1 in
the endothelium (Fig 6A and B, and Movies EV1 and EV2). Hence,
also in vivo endothelial Ccn1 regulates the crosstalk between cancer
and endothelial cells by promoting cancer cell binding. Next, we
provide evidence that vascular Ccn1 controls cancer cell metastasis.
To localize the knockout of Ccn1 within the vascular regions, we
exploited a cell-penetrating, soluble form of Cre, fused to the His-
TAT-Nuclear localization sequence tag (HTNC). The HTNC recom-
bines loxP sites when used in cell culture (Peitz et al, 2002), and
targets endothelial cells when injected in the circulation of mice
(Giacobini et al, 2014). Ex vivo addition of HTNC to mouse lung
endothelial cells isolated from Ccn1fl/fl mice reduced Ccn1 protein
levels (Appendix Fig S4A). Moreover, serial intravenous treatment
with HTNC of B16F10-transplanted Rosa26flSTOP-tdRFP mice (Luche
et al, 2007) induced efficient recombination in the vasculature of
some tumor regions, as shown by immunohistochemistry staining
for RFP (Appendix Fig S4B and C). Little recombination was
measured in the lungs (Appendix Fig S4B and C) and no recombina-
tion in circulating myeloid cells, as assessed by the absence of RFP-
positive signal in cells isolated from blood and bone marrow
(Appendix Fig S4D). Furthermore, a strong staining for Ccn1 was
measured in blood vessels of the B16F10 tumors (Appendix Fig
S4E), which highlights the relevance of this tumor model for our
study. Ccn1fl/fl mice were serially treated with HTNC (Fig 6C).
◀ Figure 5. Endothelial N-cadherin promotes interaction with cancer cells.A Representative immunofluorescence analysis and quantification for N-cadherin (CDH2) in HUVECs cultured for 24 h on FN-coated PAGs or FN-coated glass showing
that the localization at the cell periphery increases with elevated stiffness, which was reduced with CCN1 knockdown. White arrowheads highlight localization of
CDH2 at the cell periphery. VE-cadherin (CDH5) staining is not altered in CCN1-silenced cells. Scale bar = 20 lm.
B Representative immunofluorescence and quantification analysis showing that more PC3 cells adhere to HUVECs cultured on FN-coated PAGs of high matrix stiffness;
however, CCN1 knockdown in the HUVECs largely prevents this increased adhesion. Scale bar = 200 lm.
C Silencing of CCN1 with a pool of siRNA (pool) or two single siRNAs (#1 and #2) in HUVECs reduces the binding of PC3 cells. siCTL n = 168, siPool n = 18, si#1 n = 83,
si#2 n = 89 fields measured from three independent experiments, each performed in three technical replicates. The significance for each siCCN1 was calculated
against each specific control.
D Silencing of CCN1 with a pool of siRNA in HUVECs or HMVECs reduces the binding of B16F1 melanoma, Lewis lung carcinoma (LLC), E0771 breast cancer, and PC3
cells. CTL n = 248, LLC/E0771 n = 90, PC3 n = 70 fields measured from three independent experiments, each performed in three technical replicates. B16F1 n = 3
averaged measurements from three independent experiments. The significance for each cell line was calculated against their specific control.
E Silencing of b-catenin (CTNNB1) with a pool of siRNA in HUVECs reduces the binding of PC3 cells. N = 90 fields assessed from three independent experiments, each
performed in three technical replicates.
F Overexpression of CCN1-GFP in HUVECs increases PC3 adhesion, which is ablated in the presence of an antibody that functionally blocks the homophilic interaction
of N-cadherin (CDH2).
G Stable shRNA expression in PC3 cells targeting either CCN1 or CDH2 decreases their binding to control HUVECs.
Data information: Data are represented as mean  SEM. For panels (A, B, and F), significance according to one-way ANOVA with Tukey’s test for multiple comparisons
(n = 3 replicate experiments). For panels (C–E and G), significance according to two-tailed unpaired t-test. ns: non-significant.
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Figure 6. Ccn1 endothelial knockout reduces cancer cell adhesion to blood vessels and attenuates metastasis.
A Box plot (1st and 3rd quartile, the line represents the median; whiskers: min to max) of intravital imaging analysis of B16F10 melanoma cells injected intradermally in
the mouse ear showing that less cancer cells adhere to and are more motile on blood vessels depleted for Ccn1 in the endothelial cells (Ccn1 KOEC) compared with
control mice expressing normal levels of Ccn1 in the vasculature (Ccn1 WT). Significance according to two-tailed unpaired t-test. WT left plot n = 16, KO left plot
n = 17, WT right plot n = 16, KO right plot n = 17 fields measured from 7 mice/group. + = mean.
B Representative images of the intravital imaging analysis showing examples of fluorescently labeled B16F10 cells which stably adhere to the blood vessel of the ear
when endothelial Ccn1 is expressed (Ccn1 WT), while transiently adhere when endothelial Ccn1 is knocked out (Ccn1 KOEC). Blood vessels were stained by intravenous
injection of fluorescently labeled anti-Pecam1. The arrowhead in each panel indicates the position of the highlighted cell at time 0 min. Scale bar = 20 lm.
C The treatment regime indicates when either HTNC or the BSA, which was used as a control, was administered by tail vein injection relative to the B16F10
subcutaneous implantation.
D Incidence of macrometastases in the lungs was decreased by HTNC treatment. N = 7 mice for each treatment group.
E The proportion of mice with detectable MLANA in the blood (= circulating tumor cells, CTCs) was decreased with HTNC treatment. N = 7 mice for each treatment
group.
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HTNC treatment had no effect on primary tumor growth, tumor
vascularization, vasculature pericyte coverage, or tumor hypoxia
(Appendix Fig S5A–F), indicating that partial depletion of Ccn1 in
the vascular regions did not alter the formation and function of the
tumor-associated vasculature. In contrast, HTNC treatment
suppressed the ability of the B16F10 cells to colonize the lung, as
evidenced by a reduced incidence of macrometastases in lung tissue
and detectable circulating tumor cells (Fig 6D and E). These data
strongly suggest a defect in cancer cell transit into the blood stream,
likely due to altered cancer cell entry into the vasculature. Support-
ing this hypothesis, we could detect almost no recombination in the
lungs of HTNC-treated mice (see above). Moreover, we assessed
that endothelial Ccn1 had no impact on metastasis formation in the
lungs using the endothelial-specific Ccn1 KO setup. Injection of
B16F10 cells in the circulation of Ccn1 KOEC and Ccn1 WTEC mice
did not show any significance decrease in lung colonization
(Appendix Fig S5G and H) and formation of metastasis in the lungs
(Appendix Fig S5I) in the absence of endothelial Ccn1. In vitro data
corroborated the role of endothelial CCN1 in cancer cell intravasa-
tion. When PC3 cells were let to adhere for 24 h onto a monolayer
of ECs, a lower degree of disruption of the endothelial monolayer
was measured when ECs were silenced for CCN1 (Fig 7A and B,
and Appendix Fig S6A). Finally, we showed that silencing of CCN1
in HMVECs did not impair the permeability of these cells when
assembled into a monolayer, while it reduced the passage of highly
invasive PC-3 TEM4-18 cells (Drake et al, 2009; Fig 7C and D,
and Appendix Fig S6B and C). Thus, we propose that endothelial
loss of CCN1 decreases cancer cell adhesion to blood vessels and
reduces metastasis, likely by regulating cancer cell entry into the
vasculature.
Discussion
The formation of metastasis relies on the cancer cells’ ability to
escape from the primary tumor site, bind to blood and lymphatic
vessels, intravasate, and exploit the blood flow to reach and colo-
nize distant sites. High tumor stiffness closely correlates with
disease progression and can drive invasion. Here we discovered
that tumor stiffness alters the CCN1/b-catenin/N-cadherin pathway
that contributes to the metastatic cascade by facilitating the bind-
ing of the cancer cells to the blood vessels. A model of our find-
ings integrated in the cancer cell metastatic process is shown in
Fig 7E.
We have explored the effect that the tumor matrix stiffness may
have on the resident and attracted endothelial cells within the tumor
environment. For this, we have used a range of physiological and
pathological stiffnesses which have been shown to influence the
endothelial phenotype. While at low physiological stiffness, such as
400 Pa, endothelial cells form capillary-like networks in 2D and
tubules in 3D matrix, at increasing stiffness endothelial cells assem-
ble into networks with larger lumens and fewer branches (Sieminski
et al, 2004; Saunders & Hammer, 2010). Analysis of the proteome of
ECs on hydrogels of physiological and pathological stiffness
revealed that ECs respond to high stiffness by upregulating
hundreds of proteins. Of those, a subset of 32, which includes
CCN1, has been previously shown by chromatin immunoprecipita-
tion assay to be under the control of mechanosensitive YAP/TAZ in
MDA-MB-231 breast cancer cells (Zanconato et al, 2015; Dataset
EV1). Conversely, the majority of proteins have not yet been related
to stiffness and provides a resource of proteins to be further investi-
gated in this context.
We demonstrate that CCN1 induces enhanced nuclear b-catenin
localization and transcriptional activity in endothelial cells and
that a key downstream effect is N-cadherin expression. It has been
previously reported that N-cadherin co-localizes with VE-cadherin
at intercellular junctions and that it acts upstream of VE-cadherin
in HUVECs and microvascular dermal endothelial cells. Indeed,
silencing of N-cadherin results in increased endothelial permeabil-
ity (Luo & Radice, 2005). While we could also observe a clear co-
localization between VE-cadherin and N-cadherin in HUVECs, the
residual levels of N-cadherin measured upon silencing of CCN1
did not affect the levels and localization of VE-cadherin and the
permeability of the cells. We envisioned that in a tumor context,
the CCN1-regulated N-cadherin levels control the heterotypic inter-
action between cancer cells and the endothelium to aid the promo-
tion of intravasation and metastasis. N-cadherin is critical for EC
attachment of melanoma and breast cancer cells and subsequent
transendothelial migration (Qi et al, 2005; Strell et al, 2007).
Ectopic N-cadherin expression in a non-metastatic prostate cancer
model induces metastatic behavior in these cells, while blocking
antibodies to N-cadherin reduced tumor growth, invasion, and
metastasis, thus demonstrating the clinical relevance of N-cadherin
interactions (Tanaka et al, 2010). Recently, high stiffness has been
shown to induce N-cadherin expression in smooth muscle cells and
fibroblasts (Mui et al, 2015), and we show that this extends to the
endothelial cells. We build on this by characterizing a molecular
mechanism within ECs, whereby the tumor-induced matrix stiffness
increases CCN1 levels, which can modulate b-catenin signaling and
consequently N-cadherin levels.
CCN1 is aberrantly expressed in many cancer types and high
levels associate with tumor aggressiveness and metastasis (Xie et al,
2001; Sun et al, 2008). In a model of lung metastasis where
MDA-MB-231 breast cancer cells are intravenously injected, CCN1
depletion in the cancer cells inhibited metastasis by reducing
extravasation to the lung and enhancing cancer cell anoikis (Huang
et al, 2017). Here we identified another mechanism through which
CCN1 plays key roles in the metastatic cascade, by mediating the
crosstalk between blood vessels and cancer cells. We show that
levels of endothelial CCN1 determine the binding between endothe-
lial and cancer cells in vivo and in vitro using co-culture assays. Our
data indicate that CCN1 controls intravasation and not extravasa-
tion. Indeed, while we found decreased incidence of metastasis in
mice partially depleted for Ccn1 in the tumor vasculature, there
were no differences in lung metastasis between Ccn1 WT and Ccn1
KOEC mice using a tail vein injection setup. However, the expression
levels of both Ccn1 and N-cadherin were rather low in the lungs of
non-tumor-bearing mice. To rule out that endothelial Ccn1 has no
roles in cancer cell extravasation at the metastatic sites, further stud-
ies are required to investigate Ccn1 regulation in the vasculature of
pre-metastatic organs.
We propose that clinical targeting of CCN1 may be beneficial in
reducing tumor growth, invasion, and angiogenesis, and we demon-
strate that targeting CCN1 in the vasculature, which is easily acces-
sible to therapeutics, could also prevent cancer intravasation and
subsequent metastasis.
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Figure 7. Reduced Ccn1 levels in endothelial cells inhibit cancer cell transendothelial migration.
A Silencing CCN1 in a monolayer of HUVECs inhibits the capability of PC3 cells to invade the endothelial monolayer, as measured by reduced number of PC3 cells that
invaded the monolayer after 24 h of co-culture (left), and reduced amount of disrupted regions of the monolayer (right). siCTL n = 21, siCCN1 n = 23 fields assessed
from one representative experiment of two.
B Representative immunofluorescence staining of (A). Red = VE-cadherin (CDH5, HUVECs); green = fluorescently labeled PC3 cells. Scale bar = 100 lm.
C Transendothelial migration assay performed with PC3 cells (clone TEM4-18) and HMVECs on transwells showing that silencing of CCN1 in HMVECs reduces the
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Data information: Bars represent mean  SEM. Significance based on two-tailed unpaired t-test.
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Materials and Methods
Cell culture
Human umbilical vein endothelial cells were isolated from freshly
collected umbilical cords using collagenase (Roche Diagnostics)
0.2% in EBM-2 media (Lonza). Cells from 3 to 5 cords were pooled.
Human adult dermal microvascular endothelial cells (HMVECs)
were purchased from Sigma (100-05a). HUVECs and HMVECs were
cultured in EGM-2 (Lonza) or EGM-2 10% FBS and no heparin,
respectively, and used for experiments up to passage six. Immortal-
ized human mammary normal fibroblasts (iNF) and cancer-
associated fibroblast (iCAF) cell lines (kindly provided by Professor
Akira Orimo; Kojima et al, 2010) and the melanoma cancer cell
lines, B16F1, B16F10, and B16F10-GFP+ (from the CRUK Beatson
Institute), were cultured in DMEM (Gibco, Thermo Fisher Scien-
tific), 10% FBS, 2 mM glutamine. The prostate cancer cell line PC3
was grown in RPMI medium (Gibco, Thermo Fisher Scientific) with
10% FBS, 2 mM glutamine. The E0771 breast cancer cells were
purchased from Tebu-Bio and cultured in RPMI with 10% FBS. The
LLC cells were purchased from Sigma-Aldrich and cultured in
DMEM with 10% FBS. All cell lines were harvested with trypsin
(0.025% in PBS + EDTA) and grown at 37°C, 5% CO2, 21% O2.
Blebbistatin was from TOCRIS. All cell lines are routinely tested for
mycoplasma. For primary antibodies, RNAi, and primers, see
Appendix Supplementary Methods.
Polyacrylamide gels for cell culture
Polyacrylamide gels were generated and coated with fibronectin as
described in the literature (Lakins et al, 2012), with minor modifi-
cations: the functionalization solution differed from the published
formulation by containing final concentrations: 0.0025% (v/v)
di(trimethylolpropane) tetraacrylate and 0.01% (w/v) bisacry-
lamide, and acrylic acid N-hydroxysuccinimide ester (Sigma A8060)
was used in place of N-succinimidyl acrylamidohexanoic acid.
MS sample preparation
For the stiffness proteome, HUVECs were SILAC-labeled in custom-
made EGM-2 medium without arginine and lysine (Lonza) and
supplemented with 13C6
15N2 L-lysine and
13C6
15N4 L-arginine
(heavy, Cambridge Isotope Laboratories) or L-lysine and L-arginine
(light, Sigma) amino acids. Forward and reverse experiments were
performed, where labeling conditions were swapped. For the
proteome of HUVECs silenced for CCN1 and those cultured on
Matrigel, a heavy SILAC-HUVEC standard was mixed at a 1:1 ratio
with each of the lysates from the non-labeled samples (triplicates for
each condition). Cell lysates were collected in 2% SDS, 100 mM
Tris–HCl pH 7.6, subsequently reduced with DTT, and boiled before
being run through a 4–12% gradient NuPAGE Novex Bis-Tris gel
(Life technologies) in MOPS running buffer (Life technologies).
Proteins were digested in-gel (stiffness and siCCN1 experiments)
(Shevchenko et al, 2006), or digested on filter using the FASP
protocol with trypsin (Promega) and peptides separated into six
fractions using on-tip strong anion exchange (SAX) chromatography
(Wisniewski et al, 2009) (Matrigel experiment). Digested peptides
were desalted using StageTip (Rappsilber et al, 2007). After removal
of acetonitrile (ACN) using speed vacuum, peptides were resus-
pended in 1% TFA and 0.2% acetic acid buffer for MS data analysis.
MS analysis
Digested peptides were injected on an EASY-nLC system coupled on
line to a LTQ-Orbitrap Elite via a nanoelectrospray ion source
(Thermo Scientific). Peptides were separated using a 20-cm fused
silica emitter (New Objective) packed in house with reversed-phase
Reprosil Pur Basic 1.9 lm (Dr. Maisch GmbH). MS data were
acquired using the Xcalibur software (Thermo Scientific) and .raw
files processed with the MaxQuant computational platform (Cox &
Mann, 2008) and searched with the Andromeda search engine (Cox
et al, 2011) against the human UniProt Consortium (2010) database
(release-2012 01, 88,847 entries). See also Appendix Supplementary
Methods.
MS comparison to proliferation datasets
Mass spectrometry datasets of ECs in different contexts were used
for comparison with the stiffness dataset. One model uses ECs
cultured on plastic at high seeding density, which are proliferative
at day 1 but at day 4 become tightly confluent and reduce prolifera-
tion to a basal rate (Patella et al, 2016). Another model cultures ECs
on soft Matrigel for 4 or 22 h, where cells are initially proliferative
and begin to undergo morphogenesis, while at later time points ECs
stop proliferating and are within a quiescent network (Patella et al,
2015). ECs are therefore either cultured on matrices of very high or
very low stiffness as a monolayer or a network, respectively.
Together, these models encompass proteins regulated with prolifera-
tion independent of the stiffness and the matrix, as well as dif-
ferences in morphogenesis and cell–cell contacts. For these two
datasets, we used a SILAC spike-in approach (Geiger et al, 2011).
In the stiffness dataset, proteins were considered regulated when
their calculated SILAC ratio was above 1 standard deviation (STD)
from the average of all the SILAC ratio calculated in both the
forward and reverse replicate experiments (Fig EV1A). The subset
of significantly regulated proteins was analyzed with STRING (ver-
sion 10.0; Szklarczyk et al, 2015). The protein–protein interaction
network was built using text mining, experiments, and databases as
evidence, and a minimum interaction score of 0.7 was required. The
functional enrichment analysis was performed with STRING using
the default parameters and the whole genome as statistical back-
ground. Data were visualized with Cytoscape (Cline et al, 2007).
The hierarchical clustering analysis (Fig 1G) was performed with
Perseus software (Tyanova et al, 2016) using Z-scored SILAC ratios.
The SILAC ratios represent the average of at least two replicate
experiments for each experimental condition.
Ethical approval of animal studies
All mouse procedures were in accordance with ethical approval
from University of Glasgow under the revised Animal (Scientific
Procedures) Act 1986 and the EU Directive 2010/63/EU authorized
through Home Office Approval (Project license number 60/4181 and
70/8645) and, for the HTNC experiment with Ccn1fl/fl mice,
approved by the Institutional Animal Care and Research Advisory
Committee of the K.U. Leuven.
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E0771 orthotopic tumors for stiffness analysis
Twelve-week-old female C57BL/6 mice were orthotopically injected
in the fat pad with 0.5 × 106 E0771 breast cancer cells in 50 ll solu-
tion 1:1, medium:Matrigel (Corning). Tumors were harvested at end
point (max size). Half of each tumor was frozen and used for atomic
force microscopy analysis and hematoxylin and eosin staining,
while the other half was formalin-fixed and paraffin-embedded and
processed for hematoxylin and eosin staining, Sirius red, 0.1%
Direct Red (41496LH, Sigma), 0.1% Fast Green (FCF, S142-2,
Raymond Lamb), diluted 1:9 in picric acid (84512.260, vWR), and
in situ hybridization staining according to the manufacturer instruc-
tion. For atomic force microscopy measurement, see Appendix Sup-
plementary Methods.
Endothelial-specific Ccn1 conditional KO mice
C57BL/6 Cdh5-CreERT2 mice (Sorensen et al, 2009; Wang et al,
2010) were bred into C57BL/6J (N6) mice carrying a loxP-flanked
Ccn1 gene (Ccn1fl/fl, Fig EV3A) and further backcrossed to N8 gener-
ation. To induce Cre activity in adult, mice were given one intraperi-
toneal injection of tamoxifen (2 mg, in sunflower seed oil) daily for
3 days. For the generation of endothelial Ccn1 expressing (Ccn1
WT) and depleted (Ccn1 KOEC) mice, Cdh5-CreERT2;Ccn1+/+ and
Cdh5-CreERT2;Ccn1fl/fl mice were used, respectively. The phenotype
of endothelial Ccn1 depletion was assessed by in situ hybridization
for Ccn1 in the lungs. Tail vein metastasis experiments with B16F10
cells are described in the Appendix Supplementary Methods.
Intravital imaging
Twelve-week-old female and male C57BL/6J Ccn1 WT or Ccn1 KOEC
were intradermally transplanted in the ear with 1 × 106 B16F10
melanoma cells, of which 67% were unlabeled and 33% were either
GFP+ or labeled with DiD cell-labeling solution (V22887, Life Tech-
nologies) in 10 ll PBS. Two days post-transplantation mice were
injected intravenously with a 50 ll of fluorescently labeled Pecam1
antibody (0.5 mg/ml). Then, anesthetic (10 mg/ml Hypnorm,
5 mg/ml Hypnovel, and water, ratio 1:1:6) was administered
intraperitoneally at 10 ll/g mouse. After 10–15 min from injection,
hairs were removed from the ears using depilatory cream (Veet)
and mice positioned on a heated stage insert containing a coverslip
kept at 37°C. The ear was gently flattened against the coverslip and
held in place with tape. Intravital imaging analysis was performed
using a multiphoton microscope system (LaVision Biotec Trimscope
2) with a Coherent Chameleon Ultra 2 ti:sapphire laser which can be
used for excitation wavelengths between 700 and 1,040 nm. A 25×
water immersion objective with a numerical aperture of 1.0 (Zeiss)
was used, which had been modified to incorporate a water chamber
to facilitate long-term imaging in an inverted geometry. Two cooled
PMT detectors were used with a 595LP dichroic (Chroma) spectrally
filtering the emission into green and red channels which were
further filtered using band-pass emission filters, 525/50 nm and
650/100 nm (Semrock), respectively. Z-stack images were taken of
about 100 lm in depth with slices at 2-lm intervals, every 90 s for
20 min. After imaging analysis, the animals were culled by cervical
dislocation and lungs and ears dissected for analysis. For intravital
imaging analysis, see Appendix Supplementary Methods.
HTNC experiments
Seven-week-old male C57BL/6 Rosa26flSTOP-tdRFP mice were injected
with either 200 lg HTNC/Tat-Cre peptide (for protein purification,
see Appendix Supplementary Methods) or BSA in 20 mM HEPES
and 0.6 mM NaCl by tail vein injection at days 3, 1, 2, 4, 6, and
10 relative to subcutaneous injection of 1.5 × 105 B16F10 melanoma
cells. Mice were culled 2 weeks post-injection. To assess the recom-
bination in lungs and tumors, tissues were formalin-fixed and
paraffin-embedded and sections stained for RFP. Two mice per
group were used. One of the two mice injected with HTNC showed
recombination in the tumor vasculature and was used for the analy-
sis. For flow cytometry analysis, blood was collected by cardiac
puncture. Bone marrow cells were isolated by flushing one femur
and tibia from each mouse with approximately 5 and 2.5 ml, respec-
tively, of RPMI/10% fetal bovine serum (FBS)/2 mM ethylenedi-
aminetetraacetic acid (EDTA). Cells were passed through a 70-lm
cell strainer forming single cell suspensions prior to red blood cell
(RBC) lysis (8.3 g NH4Cl, 1.0 g KHCO3, 37.2 mg Na2EDTA, 1 l
dH2O, pH 7.2–7.4) and flow cytometry analysis (see Appendix Sup-
plementary Methods).
Ten- to eleven-week-old female and male C57BL/6 homozygous
Cyr61/Ccn1fl/fl mice were injected with either 200 lg HTNC/Tat-Cre
protein or BSA in 20 mM HEPES and 0.6 mM NaCl by tail vein
injection at days 2, 1, 0, 1, 2, 5, 7, 10, and 14 relative to subcuta-
neous injection of 1.5 × 105 B16F10 melanoma cells. Mice were
treated with pimonidazole on day 26 before being culled, and the
primary tumor, lungs, and blood were collected for analysis (n = 7
mice for each treatment group). Tumor volume was determined by
the formula: volume = p*[d2*D]/6, where d and D are the minor
and major tumor axes, respectively. Circulating tumor cells were
isolated from the blood, and the RNA was extracted for the analysis
of melanin A by RT–PCR. Whole tumor sections were imaged as a
tile scan and were analyzed by a macro used in ImageJ. The chan-
nels were split before the individual images were put together into
individual mosaic images for each channel and subsequently
merged. Regions of interest were included or excluded from the
analysis generating a “zone”. Total Meca32 (green) and co-localiza-
tion with Ng2 (red) within the zone were measured.
Statistical analysis
Statistical analysis was carried out using GraphPad Prism software
(GraphPad Software, Inc.). The P-value was calculated according to
the two-tailed unpaired t-test or the one-way ANOVA with Tukey’s
multiple comparisons test, as specified for each experiment. All fig-
ures are representative of at least three biological replicates  SEM,
unless stated otherwise. For animal studies, no statistical methods
were used to determine the sample size. When animals from the
same cohort were used, these were randomly allocated in the dif-
ferent groups. Data obtained from animal experiments were blindly
assessed. Results were indicated as outliers by GraphPad Prism soft-
ware were removed from the analysis.
IHC and in situ hybridization and quantification, Western blot,
Immunofluorescence staining, b-catenin luciferase activity assay,
cancer cell adhesion to EC monolayer and transendothelial migra-
tion, and permeability assay protocols can be found in the
Appendix Supplementary Methods.
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Data availability
The .raw MS files and search/identification files obtained
with MaxQuant have been deposited to the ProteomeXchange
Consortium (http://proteomecentral.proteomexchange.org/cgi/Ge
tDataset) via the PRIDE partner repository (Vizcaino et al, 2013)
with the dataset identifier PXD003316. Comparison proteins were
regulated by high stiffness in HUVECs and YAP/TAZ gene targets
identified by ChIP in MDA-MB-231 (Zanconato et al, 2015).
Expanded View for this article is available online.
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